Irbesartan + Hidroclorotiazida Tolife

Irbesartan, the active ingredient in Irbesartan + Hidroclorotiazida Tolife, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It treats hypertension in adult patients, often in combination with a thiazide diuretic to improve blood‑pressure control. GNH USA supplies Irbesartan + Hidroclorotiazida Tolife as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is an antihypertensive combination that lowers elevated blood pressure through dual mechanisms. - Essential hypertension: reduces systolic and diastolic pressure to target levels. - Hypertension with fluid retention: adds diuretic effect to improve volume control. - Hypertension requiring combination therapy: provides both ARB and thiazide actions in a single tablet.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Significant drop in blood pressure (hypotension) - Allergic reactions such as rash or angioedema - Elevated blood urea nitrogen or creatinine levels - Hyperuricemia or gout flare

Patients should be monitored regularly for blood pressure, renal function, and electrolyte balance. - Blood pressure monitoring: check regularly to avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics. - Caution in elderly: start at lower doses due to increased sensitivity. - Avoid in severe liver disease: impaired metabolism may increase drug exposure. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines that affect blood pressure, renal function, or electrolyte balance. Major Interactions (Avoid): - Aliskiren (combined use with ARBs can increase renal risk). - Potassium‑sparing diuretics or supplements (risk of hyperkalaemia). - Lithium (increased lithium levels and toxicity). - ACE inhibitors (additive effect on potassium and renal function). - NSAIDs (may reduce antihypertensive efficacy and impair renal function).

Moderate Interactions (Monitor Closely): - Other antihypertensives (potential additive hypotensive effect). - Antidiabetic drugs (possible alteration of glucose control). - Antimicrobials such as trimethoprim‑sulfamethoxazole (may affect potassium). - Corticosteroids (enhance sodium retention). - CYP2C9 inhibitors (may increase hydrochlorothiazide levels).